View Older Stories View More Recent Stories

Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 5, 2017 12:31PM Sanofi : Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 3, 2017 11:40AM Santander Donates $2 Million To Relief Efforts In Puerto Rico In The Aftermath Of Hurricane Maria
Sep 28, 2017 01:02AM Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 28, 2017 01:00AM Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 20, 2017 07:00AM Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 07:00AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 16, 2017 02:18AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:18AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:15AM Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017 01:00AM Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sep 11, 2017 01:00AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 8, 2017 01:00AM Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 01:00AM Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Aug 25, 2017 08:00AM Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Jul 25, 2017 09:00AM Santander Bank Selects Docutech’s™ ConformX™ to Optimize Loan Processing Efficiency with Compliant, Automated Document Generation
Jul 21, 2017 07:32AM Sanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:31AM Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 17, 2017 06:00AM Solar Alliance Completes Solar Installation at William Shatner's LA Home
Jul 11, 2017 10:44AM Santander And New England Revolution Announce 2017 Santander Soccer Scholars(SM) Program
Jul 10, 2017 09:32AM Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
Jul 10, 2017 09:30AM Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without I
Jun 27, 2017 01:00AM Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 11, 2017 11:02AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:01AM Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 11, 2017 11:00AM Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
Jun 5, 2017 06:28AM Regeneron (REGN) & Sanofi (SNY) Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at ASCO Meetings
Jun 4, 2017 10:00AM Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 4, 2017 10:00AM Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2017 05:53PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:47PM Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 22, 2017 05:46PM Regeneron (REGN), Sanofi (SNY) Announce FDA Approval of Kevzara for RA
May 22, 2017 05:45PM Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
May 11, 2017 08:30AM Allegra® Allergy Gears Up for Bike to Work Day Across the U.S.
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
May 2, 2017 08:30AM Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment
Apr 28, 2017 01:02AM Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
Apr 28, 2017 01:00AM Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Apr 25, 2017 08:00AM Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 25, 2017 08:00AM Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Apr 24, 2017 01:01AM Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Apr 24, 2017 01:00AM Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Apr 5, 2017 07:00AM William Shatner "Joins the Alliance" to Promote the Benefits of Solar Energy
Mar 28, 2017 01:50PM Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval
Mar 28, 2017 11:41AM Regeneron (REGN) and Sanofi (SNY) Announce FDA Approval of DUPIXENT to Treat Moderate-to-Severe Atopic Dermatitis
Mar 28, 2017 11:40AM Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
View More Recent Stories View Older Stories